<DOC>
	<DOCNO>NCT00617942</DOCNO>
	<brief_summary>Q3week carboplatin weekly abraxane trastuzumab neoadjuvant therapy resectable unresectable HER2+ ( stage IIa-IIIb ) breast cancer</brief_summary>
	<brief_title>Neoadjuvant Carboplatin , Weekly Abraxane Trastuzumab HER2+ Breast Cancer</brief_title>
	<detailed_description>Our goal develop induction chemotherapy regimen pCR rate 50 % HER2+ patient without expose patient toxicity anthracycline-based regimen . A minimum 60 evaluable patient accrue study . We assume observe pCR ( near pCR ) rate 70 % . Assuming 10 % patient inevaluable primary endpoint ( pCR ) , least 54 evaluable patient . With number , 90 % power , 1-sided alpha error 0.05 , demonstrate pCR rate exceed 50 % novel regimen .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically document adenocarcinoma breast ANC &gt; 1000 cell Female ; age &gt; 18 ; Zubrod PS 01 Platelets &gt; 100,000 Stage IIAIIIB disease Total bilirubin &lt; = ULN No evidence metastatic disease Not pregnant lactate No prior systemic therapy breast cancer Serum Creatinine &lt; 1.5 mg/dl Creat Cl &gt; 30 ml/min Serum ALT &lt; 2.5 x ULN ER , PR HER2 status require LVEF ( MUGA/echo ) WNL No baseline &gt; 2 neuropathy Hemoglobin &gt; 9.0 gm/dl HER2+ , define IHC 3+ FISH ratio &gt; 2.0</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>